Drug Profile
GW 273225
Alternative Names: GW273225Latest Information Update: 02 Aug 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Class Antiepileptic drugs; Neuropsychotherapeutics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Bipolar disorders; Epilepsy
Most Recent Events
- 19 Dec 2013 Discontinued - Phase-I for Bipolar disorders in United Kingdom (PO)
- 19 Dec 2013 Discontinued - Phase-I for Epilepsy in United Kingdom (PO)
- 31 Mar 2007 Phase-I clinical trials in Bipolar disorders (in healthy volunteers) in United Kingdom (PO)